Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2017-06-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
第八届董事会第三次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the resolution of the company's eighth board of directors' third meeting. It specifically announces the appointment of Ms. Xu Haizhen as the company's financial director. The content focuses on board decisions and management appointments, including voting results and biographical details of the appointed individual. There is no financial data, earnings information, or regulatory filing references. The document fits the category of announcements related to changes in the company's board or senior management.
2017-06-09 Chinese
独立董事关于聘任高管的独立意见
Board/Management Information Classification · 95% confidence The document is a formal independent opinion from independent directors regarding the appointment of a senior executive (financial director) at Jiangsu Sihuan Bio Co., Ltd. It references compliance with relevant laws, regulations, and company articles, and confirms the suitability of the candidate. There is no financial data, no report attached or referenced as published, and no mention of voting results or meeting materials. This is a management/board-related announcement about a senior management appointment, fitting the Board/Management Information (MANG) category.
2017-06-09 Chinese
关于补选公司第八届监事会职工监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new employee representative supervisor to the company's supervisory board, including a brief resume of the elected individual. It is a formal disclosure about a change in the company's board-level personnel. There are no financial statements, audit information, or report publications. The content fits the category of Board/Management Information, as it announces a change in the company's supervisory board members.
2017-06-05 Chinese
关于职工监事辞职的公告
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the resignation of an employee supervisor from the company's supervisory board. It includes no financial data, no report attachments, and no mention of financial results or regulatory filings beyond the resignation notice. The content is about a management change, specifically a board/supervisory member change. Therefore, it fits the category of Board/Management Information (MANG). The document length is very short (474 characters), confirming it is an announcement rather than a full report.
2017-06-02 Chinese
关于公司办公地址变更的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement about the change of the company's office address. It does not contain financial data, management changes, voting results, or any report publication. It is a regulatory announcement informing the public about the address change. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-06-02 Chinese
关于诉讼的进展公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the progress of a litigation case involving the company. It details the background of the lawsuit, the court's previous ruling, the appeal filed by the opposing party, and the potential impact on the company's profits. The document does not contain financial statements, audit results, or detailed financial data. It is a legal update about ongoing litigation rather than a full legal proceeding report or financial report. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is short and focused solely on litigation progress, confirming it is not an annual report or earnings release. Hence, the classification is LTR with high confidence.
2017-05-31 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.